secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-060671
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Q3 net loss $22.3M; cash $360M into 2026; TNG348 Fast Track
-----------------------------------------------------------------

- Cash, equivalents and marketable securities $359.9M at Sept 30, 2023; runway into 2026.
- Net loss $22.3M ($0.23/share) vs $29.1M ($0.33/share) in Q3 2022; net loss $71.0M YTD.
- TNG348 (USP1 inhibitor) granted FDA Fast Track for BRCA1/2-mutant cancers; IND cleared; phase 1/2 start expected H1 2024.
- TNG908 (PRMT5) dose escalation ongoing; additional clinical data expected in 2024.
- Kanishka Pothula appointed to Board; Jannik Andersen promoted to CSO; $80M private placement closed in August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023060671/0000950170-23-060671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023060671/tngx-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer